We discussed the current literature regarding the role of allo HCT in 
the era of BV and PD1 blockade for HD.

Patients with cHL who are ineligible for auto-HCT or relapse after 
auto-HCT have historically had a poor prognosis with a median survival 
of 2 years or less.25⇓⇓-28 Brentuximab achieves high response rates 
(75%) in this setting, and a subset of patients who achieve a CR with BV 
(∼33%) will experience lengthy remissions (estimated 5-year PFS 52%).29 
Even so, a large majority of patients treated with BV will relapse; 
moreover, given the increasing use of BV in earlier lines of therapy,30 
many patients with post–auto-HCT relapse will have already received BV. 
The anti-PD-1 monoclonal antibodies nivolumab and pembrolizumab are both 
approved in this setting and are associated with overall response rates 
(ORRs) of ∼70%.1⇓⇓⇓-5 Here too a subset of patients can achieve durable 
remissions.1⇓⇓-4,31,32 However, based on the phase 1/2 data available to 
date, it appears that a majority of patients will relapse within 1 to 2 
years of starting PD-1 blockade, and it is not clear yet what proportion 
of patients, if any, can attain long-term remission. Thus, for patients 
responding to anti-PD-1 mAb’s, allo-HCT represents the only modality 
with known curative potential.

Presenter: Prof. Spyridonidis

Participants: Dr Liga, Dr Spyridis, Dr Aggelinas